Our Science
Pipeline
A new class of antifungal. Powerful. Different.
At SCYNEXIS, we believe that our innovative fungerp class of antifungals could be essential therapy in the treatment of multiple serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and more. Learn more about our pipeline below.
SCY-247
Candida auris and other drug-resistant fungal infections*
*Partially supported by NIH grants
IND-enabling
IV & Oral
IV & Oral
Ibrexafungerp
Invasive Candidiasis and Other Refractory Fungal Infections
Phase 3
Partner:
Vulvovaginal Candidiasis (BREXAFEMME®)
Approved
Partner:
GSK has an exclusive license for the development and commercialization of ibrexafungerp for all indications globally, except in the greater China region and certain other countries.